A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : HPS / Heart Protection Study

[Related PubMed/MEDLINE]
Total Number of Papers: 34
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   HPS  (>> Co-occurring Abbreviation)
Long Form:   Heart Protection Study
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials. HDL
2019 Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk. AACE, ACS, apoB, ASCVD, CHD, IMPROVE-IT, IVUS, LDL-C, MACE, MI, RCTs, REVERSAL
2014 Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. CARDS, CVD
2012 Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly. CVD, LDL-C
2011 Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. RR
2010 Statins: cost analysis in Indian scenario from eight major clinical trials. AFCAPS, ASCOT-LLA, CARE, CER, CHD, LIPID, NNTB, WOSCOPS
2009 Statin therapy and risk of developing type 2 diabetes: a meta-analysis. ASCOT, CORONA, LIPID, RRs, WOSCOPS
2007 Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. CARDS, CHD, GREACE
2007 Atorvastatin: its clinical role in cerebrovascular prevention. CARE, CHD, GREACE, TIA
10  2007 Beyond lipid lowering: the anti-hypertensive role of statins. ---
11  2007 New frontiers in the management of type 2 diabetes. TZDs, UKPDS
12  2007 Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. PAD
13  2006 Lipid lowering therapy in the elderly: is there a benefit? CVD, PROSPER
14  2006 Statins, fracture risk, and bone remodeling: What is true? LIPID
15  2006 [Do statins have a place for cardiovascular prevention in elderly people?]. ---
16  2005 A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus? ASCOT, CARDS, CARE, DAIS, HDL-C, LDL-C
17  2005 Long-term risk reduction: who needs treatment? CARDS, CVD, LDL-C
18  2005 What impact will current trial data have on future guideline recommendations? ASCOT-LLA, CVD, LDL, SCORE, TNT
19  2004 Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention: the search for superior treatment. CHD, LDL-C
20  2004 Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. CHD, FIELD, HDL-C, LDL-C, SEARCH, TNT
21  2004 Simvastatin: a review. CHD, HMG-CoA, LDL-C
22  2004 The importance of aggressive lipid management in patients at risk: evidence from recent clinical trials. ASCOT-LLA, CHD, LDL-C, REVERSAL
23  2004 [Treatment with statins of the elderly]. ---
24  2003 Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal. LDL
25  2003 Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety. LDL
26  2003 Reducing major vascular events among VA primary care patients: an extraordinary opportunity. ---
27  2003 Risks and benefits of continued aggressive statin therapy. ACC, AHA, HMG-CoA, LDL-C, NHLBI
28  2003 Statins and renal function in patients with diabetes mellitus. GREACE
29  2003 The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. CAD
30  2003 Treatment of atherosclerosis in the new millennium: is there a role for vitamin E? CHAOS, GISSI, HOPE
31  2003 [Secondary prevention after ischemic stroke]. PROGRESS
32  2002 Managing dyslipidemia in the high-risk patient. ATP, CAD, FDA, LDL-C, NCEP
33  2002 Protecting the heart: a practical review of the statin studies. AVERT, CARE, IHD, LIPID, MIRACL, WOSCOPS
34  2002 The MRC/BHF Heart Protection Study: preliminary results. CHD, TC